Next Investors logo grey

NTI Complete In Vitro Studies on Cannabis Strains, Clinical Trials Await


Published 21-DEC-2020 11:02 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Neurotech International Ltd (ASX:NTI) has today confirmed the successful completion of in-vitro studies using human brain cells to assess and validate the anti-inflammatory and neuro-modulatory properties of its proprietary DOLCE/NTI cannabis leads.

In vitro studies are those done in the laboratory within the confines of a test tube or laboratory dish. Neurotech’s in vitro studies have shown the superiority of the DOLCE/NTI strains over CBD alone and now pave the way for future studies, including phase 1 clinical trials.

Neurotech has been undertaking a series of in-vitro studies to assess the neuroprotective, anti-inflammatory and neuro-modulatory activities of the proprietary DOLCE/NTI cannabis leads CBDA, CBDP, CBDB.

The DOLCE/NTI strains are unique in that they contain minimal THC (<0.3%), which may result in a less onerous regulatory pathway to commercialisation (any cannabis strain with a THC level above 0.3% is regulated as a narcotic).

The in-vitro studies were conducted at three leading independent laboratories – Monash University, University of Wollongong and RMIT University.

Neurotech previously reported the mode of action and powerful neuro-protective and modulatory properties of these unique strains versus CBD alone. These in vitro findings have been further validated in these final trials.

As many as one billion people suffer from a neurological disorder

DOLCE/NTI strains have shown to significantly improve neuronal cell health, cell viability and have the potent ability to reduce inflammation compared with CBD alone.

All these physiological processes are vital in managing disorders with unmet need for therapies including; Autism, Epilepsy, ADHD, Alzheimer’s disease and related neurological disorders.

The World Health Organisation estimated that in 2006, as many as ‘one billion people’ suffered from a neurological disorder. Without effective treatments or cures, the number of those affected by neurological disorders will continue to increase as the world’s population grows.

With a range of disorders impacting so many people, the market opportunity for Neurotech is large. The global market size is estimated to be $112BN per year by 2027, growing at a rate of 5% per annum.

Path cleared for Phase 1 clinical trials

Neurotech’s in vitro studies have shown the superiority of the DOLCE/NTI strains over CBD alone and now pave the way for future studies, including phase 1 clinical trials.

Phase 1 clinical study preparations are currently underway to develop the optimum delivery and dosage forms.

Commencement of stage 1 is expected in Q1/ 2021. Clinical trials will be conducted under the guidance and supervision of A/Professor Michael Fahey (Head of Paediatric Neurology, Monash Children's Hospital).

A/Professor Fahey recently completed his prestigious Fulbright scholarship in the USA and has extensive experience in the clinical development and management of medicinal cannabis in children with autism and related neurological disorders.

A/Prof Fahey and his team are experts in neurodevelopment and neuroprotection studies across various patient groups. "Preclinical studies suggest that these strains exhibit potent and unique properties when compared to CBD alone and warrant the further assessment of these strains in phase 1 clinical trials," said A/Prof Fahey.

“These final trial results are very encouraging, in particular, the powerful anti-inflammatory mode of action of our strains compared to CBD alone,” said Brian Leedman, Chairman of Neurotech. These results demonstrate that the DOLCE/NTI leads may have a broader application in relation to the management and treatment of a number of neurological disorders”.

Neurotech continues to progress the development of its propriety cannabis strains, and is setting itself up for an active first half in 2021.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.